This article is more than 5 years old. Information may no longer be current.

Wright Medical features new innovations at AOFAS Annual Meeting

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Wright Medical Group N.V. announced it will highlight new innovations, including the Prostep Minimally Invasive Surgery System and Augment Injectable Bone Graft, at the American Orthopaedic Foot & Ankle Society Annual Meeting being held in Boston from July 11-14, 2018.

“We have continued to expand our best-in-class foot and ankle product portfolio to meet the needs of orthopedic surgeons and patients and further enhance our leadership position in the fast-growing lower extremities and biologic markets,” Robert Palmisano, president and CEO of Wright Medical, said in a company press release.

Used to treat a variety of forefoot and hindfoot pathologies, the release noted the Prostep System provides a minimally invasive, procedurally integrated solution that features specifically designed implants and instrumentation for percutaneous surgery of the foot.

“The launch of our Prostep Surgery System is a key new product launch for our core foot and ankle business and highlights our ability to help physicians provide a minimally invasive procedure option to patients to reduce pain and provide a more rapid recovery time, ultimately resulting in higher patient satisfaction,” Palmisano said.

The first clinically proven injectable protein therapeutic to come to the U.S. orthopedic market, the Augment Injectable Bone Graft offers an alternative to autograft in ankle and hindfoot fusion procedures, according to the release.

“The U.S. launch of PMA-approved Augment Injectable expands our proven Augment franchise to meet the needs of foot and ankle surgeons in the U.S. with a safe and effective alternative to autograft that includes significantly improved handling characteristics to enable easier and more precise delivery to the fusion site,” Palmisano said. “Augment Injectable is expected to deliver sustainable growth in the U.S. for the Augment Regenerative Solutions platform over the next several years.”

The Salvation 2 Limb Reconstruction System, Invision Total Ankle Revision System with Prophecy Preoperative Navigation and OrthoLoc Universal Anterior Fusion Plate will also be featured at the AOFAS Annual Meeting, according to the release.

Reference:

phx.corporate-ir.net/phoenix.zhtml?c=129751&p=irol-newsArticle&ID=2357760